Adolfsson J, Rönström L, Löwhagen T, Carstensen J, Hedlund P O
Department of Urology, Karolinska Hospital, Stockholm, Sweden.
J Urol. 1994 Nov;152(5 Pt 2):1757-60. doi: 10.1016/s0022-5347(17)32379-0.
From 1978 to 1982, 172 patients with stages T1 to 3NxM0 prostate cancer were included in a surveillance protocol with deferred treatment on symptomatic progression. Median patient age at diagnosis was 68 years (range 38 to 89 years). Mean followup was 80 +/- 32 months. Of the patients 58% had local and 19% had distant progression, and 52% had received treatment at followup. Disease specific survival rate at 10 years was 80% for the total series, 84% for the subgroup with stage T1 or T2 tumor and 92% for those with stage T1 or T2 tumor who were less than 70 years old at diagnosis. For the subgroup with stage T3 tumor the disease specific survival rate at 9 years was 70%. In all subgroups the competing mortality rate was higher than the prostate cancer mortality rate. Deferred treatment appears to be an acceptable option for patients with tumor clinically confined to the prostate and a life expectancy of 10 years or less.
1978年至1982年，172例T1至3期NxM0前列腺癌患者被纳入一项监测方案，即症状进展时推迟治疗。诊断时患者的中位年龄为68岁（范围38至89岁）。平均随访时间为80±32个月。患者中58%有局部进展，19%有远处进展，52%在随访时接受了治疗。整个系列的10年疾病特异性生存率为80%，T1或T2期肿瘤亚组为84%，诊断时年龄小于70岁的T1或T2期肿瘤患者为92%。T3期肿瘤亚组的9年疾病特异性生存率为70%。在所有亚组中，竞争性死亡率高于前列腺癌死亡率。对于临床局限于前列腺且预期寿命为10年或更短的患者，推迟治疗似乎是一个可接受的选择。
